Stock Analysis

Sprout Social Maintains 'Buy' Rating Despite Stock Challenges, Shows Resilient Growth

Sprout Social Maintains 'Buy' Rating Despite Stock Challenges, Shows Resilient Growth

Sprout Social demonstrates strong financial performance and strategic potential despite recent stock decline, with analyst Needham maintaining a 'Buy' rating and highlighting the company's robust social media management platform.

May 29, 2025
Stonegate Initiates Coverage on Alpha Cognition, Projects Strong Growth for New Alzheimer's Drug

Stonegate Initiates Coverage on Alpha Cognition, Projects Strong Growth for New Alzheimer's Drug

Alpha Cognition's newly approved Alzheimer's drug ZUNVEYL is positioned to address a significant market gap with a potentially safer treatment option, as Stonegate Capital Partners initiates coverage with a valuation range of $27.62 to $38.44 per share.

February 4, 2025